Communique of GTTAC meeting of 19 October 2020
This Communiqué covers matters considered at the 21st video conference of the Gene Technology Technical Advisory Committee (19 October 2020).
Licence application DIR 174 from Biocelect Pty Ltd is for the import, transport, storage and disposal of a genetically modified (GM) cholera vaccine, Vaxchora®, as part of its commercial supply in Australia.
The Committee noted the key points in the consultation RARMP including the conclusion that the proposed dealings pose negligible risks to people or the environment. GTTAC discussed the potential for harm from the vaccine strain acquiring one or more antibiotic resistance genes, and agreed this did not impact the conclusion that the risks are negligible.